title: Radiobiological modifiers in clinical radiation oncology: current reality and future potential.
abstract: Radiation therapy can successfully ablate tumors. However, the same ionization process that destroys a cancer can also permanently damage surrounding organs resulting in unwanted clinical morbidity. Therefore, modern radiation therapy attempts to minimize dose to normal tissue to prevent side effects. Still, as tumors and normal tissues intercalate, the risk of normal tissue injury often may prevent tumoricidal doses of radiation therapy to be delivered. This paper will review current outcomes and limitations of radiobiological modifiers that may selectively enhance the radiosensitivity of tumors as well as parallel techniques that may protect normal tissues from radiation injury. Future endeavors based in part upon newly elucidated genetic pathways will be highlighted.
authors.forename: Ron R
authors.initials: RR
authors.lastname: Allison
mesh_terms: D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000532:radiotherapy*; D009389:Neovascularization, Pathologic / Q000532:radiotherapy; D011832:Radiation Injuries / Q000517:prevention & control*; D018787:Radiation Oncology; D011836:Radiation Tolerance; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
chemical_list: D011837:Radiation-Protective Agents; D011838:Radiation-Sensitizing Agents
keywords: radiation protectors; radiation sensitizers; radiation therapy; radiomodulators